This report was first published by Endpoints News. To see the original version, click here
Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday.
Patients in the REDEFINE 4 trial who were taking CagriSema lost 20.2% of their weight after 84 weeks. Those taking Lilly’s drug lost 23.6%.
您已阅读9%（396字），剩余91%（3784字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。